C-A3TNHemostemix
autologous stem cells, angiogenic cell precursors, ischemia
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-A3TN
C-A3TNC-A3TNautologous stem cells, angiogenic cell precursors, ischemia
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Most amputations begin years before a wound appears, when microcirculation quietly fails. As ischemia progresses from small vessels to larger ones, risk of critical limb ischemia (CLTI) and amputation rises. In this short, Hemostemix CEO Thomas Smeenk explains why circulation is the root issue and how investigational, autologous approaches like ACP-01 (angiogenic cell precursors) are being studied to support blood flow, wound care, and limb preservation in advanced PAD/CLTI. If you’re a clinician or a patient facing “no-option” decisions, learn how research in regenerative medicine and stem cell therapy is exploring new pathways for limb salvage. 🔔 Be sure to subscribe and tap the notification bell so you don't miss any exciting news and updates! 🔗 Learn more at www.hemostemix.com 📞 Call us: (905) 580-4170 💬 Share this to raise awareness & reach those in need. 🧬Connect with Hemostemix: 💼LinkedIn: https://www.linkedin.com/company/3212019 🗣️Facebook: https://www.facebo
In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, CEO, and President Thomas Smeenk about the significance of engaging Dr. Chris McNorgan, Ph.D., to drive a license agreement of NCP-01 (Neural Cellular Precursors) with a neural electrode brain implant company. Dr. McNorgan directs the Computational Cognitive Neuroscience (CCN) laboratory at the University of Buffalo and his research – the neural bases of cognition, including AI methods to decode and simulate neocortical representations of knowledge and motor intention – is directly relatable to neural electrode-based implantation. With Dr. McNorgan’s appointment, it brings another expert onto the team that includes Dr. Henderson, a neurosurgeon, and Dr. Inna Sorel, the mother of the invention of NCP itself, to help drive the legitimacy of licensing the NCP-01 platform. Thomas discusses the potential for licensing and partnerships to take NCP-01 to the neural electrode-b
230120 Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. Under the Letter of Commitment, the MUHC Foundation will fund $250,000 of the clinical trial expenses and partner with Hemostemix, Dr. Nadia Giannetti and Dr. Renzo Cecere to complete a phase II double blind randomized clinical trial of ACP-01 as a treatment of ischemic cardiomyopathy at the McGill University Health Centre. In 2020, the MUHC Foundation launched its $200 million Dream Big Campaign to change the course of lives and medicine. The Dream Big Campaign is designed to ensure bold innovations like ACP-01 are well supported by philanthropy. To reach that goal, Hemostemix and the MUHC Foundation are committed to working together with federal and provincial partners alongside donors to fund the phase II clinical trial at the McGill University Health Centre. Ju
Visit our website to learn more: https://hemostemix.com/ Join the conversation on Telegram: https://t.me/hemostemix
In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenk talks about Hemostemix achieving a major milestone this week by announcing it had successfully settled all litigation regarding its ownership of its intellectual property and the market’s immediate positive reaction. In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here), Thomas Smeenk talks about Hemostemix’s portfolio of autologous stem cell therapies that uses patient’s own blood to save limbs from amputation, treat heart diseases and other conditions of ischemia. With 91 patents issued worldwide, Thomas says that with the successful return of all of its intellectual property and clinical trial data, Hemostemix is now cleared to continue to move forward. Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel. About Hemostemix Inc. Hemostemix is a publicl
Hemostemix CEO Thomas Smeenk joined Steve Darling from Proactive to share news about the company that is using stem cell therapy to aid in a number of diseases. Smeenk telling Proactive more about their lead product ACP-01 which is looking to treat CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients and right now is the subject of a randomized, placebo-controlled, double blind trial for safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. Smeenk also talked about what to expect this year including Phase 2 trial results.
In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXF) about Hemostemix’s recent “blockbuster” news release on collaborating with world famous Dr. James Shapiro to Treat Type 1 Diabetes and about trademarking “Your Fountain of Youth”. In this InvestorIntel interview, Thomas Smeenk said that Dr. James Shapiro is well known and respected for creating the Edmonton Protocol for the treatment of Type 1 Diabetes. Thomas went on to provide an update on Hemostemix’s technology platform that uses stem cells from a patient’s own blood to treat the heart-damage following a heart attack. Providing an update on Hemostemix’s recently closed oversubscribed private placement, he went on to explain how Hemostemix has found a “Fountain of Youth.” About Hemostemix Inc. Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pio
#Hemostemix (TSXV: HEM; OTCQB: HMTXF) is a clinical-stage #biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. Three months after the GCFF #healthcare event, we are excited to meet with Thomas Smeenk, CEO and Co-founder of Hemostemix again for the latest updates. On Sep 14, Hemostemix announced the first of a series of 2021 video interviews with ACP-01 recipients: what the successful compassionate treatment of ischemic cardiomyopathy looks like after 13 years. Hemostemix’s lead technology, ACP-01, is expandable, and is a pioneering approach to the treatment of ischemic diseases. It is also undergoing a phase II clinical trial for Critical Limb Ischemia, and the result will be coming up in Q3. Thomas shared with us some clinical trial stories in this episode as well. Watch today’s CEO Interview to learn more about Hemostemix. Hemostemix (TSXV: HEM; OTCQB: HMTXF) 是一家臨床階段的生物科技公司，專注於開發和商業化專有的自體細胞療法治療缺血性疾病。 Hem
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO ofHemostemix Inc. (TSXV: HEM | OTC: HMTXF) about the Phase II Clinical Trial on Hemostemixs ACP-01 which has the potential to treat patients with severe critical limb ischemia. In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to say that Hemostemix is in the process of completing the source document verification. With about 60% of source documents verified, Thomas said that they expect the source document verification to be complete within the year. To watch the full interview,click here About Hemostemix Inc. Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopath
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXF) about the Phase II Clinical Trial on Hemostemix’s ACP-01 which has the potential to treat patients with severe critical limb ischemia. In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to say that Hemostemix is in the process of completing the source document verification. With about 60% of source documents verified, Thomas said that they expect the source document verification to be complete this year. About Hemostemix Inc. Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-
MONTE CARLO, MONACO – (July 2, 2021) – The most powerful and influential investors representing elite family offices travelled from around the world to convene in Monaco at Sir Anthony Ritossa's 15th Global Family Office Investment Summit under the High Patronage of His Serene Highness Prince Albert II of Monaco.
Emerging Growth Conference 5/26/21 Thomas Smeenk Co-Founder, President, CEO of Hemostemix, Inc., (OTC Pink; HMTXF) (TSX: HEM) presented on the Emerging Growth Conference on May 26, 2021. Hemostemix, Inc., (OTC Pink; HMTXF) (TSX: HEM) is a winner of the World Economic Forum Technology Pioneer Award, is an autologous stem cell therapy company.
In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXF), about Hemostemix’s autologous stem cell therapy and why he calls the technology “the fountain of youth.” In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to say that Hemostemix’s lead product ACP-01 works by treating ischemia (lack of blood circulation) in a patient’s body. The technology has already been used to treat around 500 patients suffering from ischemia in the heart, arteries, and limb. He added that using the technology many patients were able to “save their limbs from otherwise certain amputations.” Hemostemix has 91 patents including a patent on the automation of production which enables the company to scale the business “exponentially” as over a million patients lose their limbs to amputation in North America alone. The technology i
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXD), about using Hemostemix’s patented autologous stem cell therapy platform to treat Ischemia and Angina with significant success in more than 500 patients. In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to give an introduction about the origin of the company and talked about the strong management team and well known board members. "I have come across some good technologies and put together a team that have succeeded," Thomas commented. Thomas also provided an update on Hemostemix's ACP-01 Phase 2 Clinical Trials. ACP-01 uses a patient’s own cells to restore blood flow to ischemic limbs and has the potential to treat a range of ischemic diseases. About Hemostemix Inc. Hemostemix is a publicly traded autologous stem cell therapy company, founded
The primary objective of this study is to determine the efficacy and safety of intramuscular injection of ACP-01, comprised of blood-derived autologous ACPs, in subjects with critical limb ischemia who are receiving standard of care therapy and have no endovascular or surgical revascularization options.
Hemostemix Inc. (HEM) Leadership & Management Team Analysis - Simply Wall St Dashboard Portfolios Watchlist Community Discover Screener NOT FOR DISTRIBUTION Hemostemix Inc. TSXV:HEM Stock Report Market Cap: CA$10.9m Portfolio Add to Portfolio Holding More actions … Portfolio Add to Portfolio Holding … Company Overview 1 Valuation 2 Future Growth 3 Past Performance 4 Financial Health 5 Dividend 6 Management 7 Ownership Other Information Stock Community View Dividend Hemostemix Management Management criteria checks 4/4 Hemostemix's CEO is Thomas Smeenk, appointed in Dec 2019, has a tenu … licable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Announcement • Oct 08 Hemostemix Inc. announced that it expects to receive CAD 0.7 million in funding Hemostemix Inc. announced a non-brokered private placement to issue 6,363,636 units at an issue price of CAD 0.11 for gross proceeds of CAD 699,999.96 on October 8, 2025. Each unit consists of one common share and one warrant. … licable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. New Risk • Aug 08 New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.6m (US$9.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small comp … licable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside of Canada. Certain directors of the company are participating in the offering. Announcement • Jun 18 Hemostemix Inc. announced that it has received CAD 0.469366 million in funding Hemostemix Inc. announced a non brokered private placement to issue 3,911,385 common shares at an issue price of CAD 0.12 for the proceeds of CAD 469,366.2 … ght not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over th
Instagram Instagram Log In Sign Up Close Never miss a post from thomassmeenk Sign up for Instagram to stay in the loop. Sign up Log in thomassmeenk and hemostemix.inc Toronto, Canada More options thomassmeenk 59w The story behind Hemostemix began with a single patient—and a lot of heart. Roger Bergersen, a former stockbroker and visionary, survived a devastating heart injury thanks to a pioneering stem cell therapy. What followed wasn’t just healing—it was a mission. From Bangkok to Canada, from patient to founder—his journey gave rise to Hemostemix and ACP-01, now helping hundreds avoid amput
Hemostemix Inc. CEO on mission to treat pain and heal wounds | Thomas Smeenk posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo
Asset->js('assets/js/cookie-banner', null, false) }}" as="script">--> --> Hemostemix Inc (CVE:HEM) Share Price | RNS News, Quotes, & Charts | HEM.V | @ element('Front/sign_in_out_buttons') --> AU UK USA AU CA Watch --> My Proactive Feed Alerts Subscriptions Bookmarks Settings Sign In News Browse Latest news IPOs Live Newsletters OTC Markets Quarterlies Small caps The Five at Five SpaceX stock surges in hotly anticipated market debut 02:12 13 Jun --> The Small Cap Weekly Wrap: IPOs, resource upgrades, biopharma milestones and more... 14:22 12 Jun --> Has Crypto lost its magic? Investors rethink … s to identify and eradicate tumours 10:38 12 Jun --> Pilbara Gold chases bigger prize as Mt York grows into major WA development story 10:37 12 Jun --> AuMEGA Metals: Can Newfoundland's next major gold discovery emerge from Cape Ray? 10:37 12 Jun --> Prescient Therapeutics seeks to provide new tools for clinicians in combating cancer 10:45 11 Jun --> Can Queensland's Taroom Trough become Australia's next major gas basin? 14:07 10 Jun --> Watch Companies Browse
You need to enable JavaScript to run this app. Loading...
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's disease
Hemostemix Appoints Dr. York Hsiang to Develop Healthcare Partnerships with First Nations Communities - GeneOnline News Skip to content Advertise Inquiries | About Us | | Events Subscribe Intelligence Menu Toggle Markets & Deals Policy & Regulation Ranking & Reports Founders’ Circle Development to Market Discovery Menu Toggle R&D Frontiers Trials & Approvals CDMO & CRO Activity Public Health Oncology Insights Infection, Immunity & Vaccination Nexus Menu Toggle AI, Tech & Digital Innovation Advanced Biologics & Biosimilars Exosomes & Delivery Precis
Hemostemix Inc. (TSX Venture: HEM.V) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 127 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> LD Micro Weekend Special (OS Edition) (1 of 1) Navigation Back to Index Overview Corporate Events Filings Financials Historical Data Share Info Time and Sales In
%PDF-1.5 %���� 2996 0 obj > endobj 3009 0 obj >/Filter/FlateDecode/ID[ ]/Index[2996 20]/Info 2995 0 R/Length 71/Prev 258956/Root 2997 0 R/Size 3016/Type/XRef/W[1 2 1]>>stream h�bbd``b`N�k@�6�$��A�s� ���AJ��X'@�v ������b``D'���`�1 endstream endobj startxref 0 %%EOF 3015 0 obj >stream h�b```� , lx�����(�1Q���u`��s����Ҷ����"l&j�gO�u[Ǭ�(�a���bJ��-O� >/Metadata 98 0 R/Outlines 225 0 R/PageLayout/OneColumn/Pages 2988 0 R/StructTreeRoot 698 0 R/Type/Catalog>> endobj 2998 0 obj >/Font >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 2999 0 obj >stream h��UKk�@�+{la�Z B … e3f28dd-7b94-4cbe-8abe-f14b4b848246 uuid:864768a9-5cc9-4618-af65-280a4b0013c3 1 application/pdf Adobe PDF Library 11.0 D:20170202201145 endstream endobj 99 0 obj >stream hޜѽ�0��[9w��&��х7�@"1.j��{�_먁�}��IH�J��y��PW2�X !�JV�02/�4���� >stream h�l�� �@�W���(��C"HҦ�����\i*�q ߾�"Z�:gq�N�\�D���`��~��밷�w��~�����RY��UrD2�q 3Xx�g吢a���rS�+��R���D��p��ӕ�"�OL��I :RS�(v�fţ3���A�֠��\�$u���`c�����A����G� endstream endobj 101 0 obj >/Filter/FlateDecode/ID[ ]/Info
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Hemostemix's ACP therapy helps Mrs. Lamb regain dignity and independence from vascular dementia. | Thomas Smeenk posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By
Hemostemix Announces Ongoing Phase II CLI Trial Abstract Accepted for Presentation by Canadian Society for Vascular Surgery - Clinical Trial Recruitment Find a Study Now Welcome to the future of clinical research recruitment Receive The Newest Study Notifications Email Text Select Page Volunteers / Patients To receive emails To receive text messages FAQs Blog Opt-Out HIPAA Privacy Policy Research Site Staff Register Login Forgot password Pricing Terms and Conditions HIPAA Digital marketing Contact Us Pharmaceutical Sponsors/ CROs Register Login Forgot password Multi-Site Pricing Terms and Cond … re clinical trial results, long-term capital requirements and future ability to fund operations, future developments in the Company’s markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Company’s operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intentio
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board September 15, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (“Hemostemix” or the “Company”) is pleased to announce the appointment of Dr. Johanne … tmental seminars. He has received several awards including the Walter-Doberauer award for aging research. "I have worked in the field of stem cell science and aging since 2000. ACP-01 is unique and its study results results are very promising," said Dr. Grillari. "I look forward to working with the other members of the SAB in support of the Company's contribution to science and commercialization goals," said Dr. Grillari. "As one of Europe's most well-regarded cell aging scie … mpany, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases … 's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievem
Puerto Rico destaca como líder mundial de Biociencias en Bio International 2024 y recibe a Hemostemix y Smartweave - AmaRie Magazine Saltar al contenido domingo, 14 de junio de 2026 AmaRie Magazine En hacer de la excelencia, la diferencia Bienvenidos Contacto Sobre Nosotros Entretenimiento Conciertos Eventos Farándula Música Radio Reseñas Teatro Televisión Entrevistas Estilo de Vida Belleza y Estética Beneficencia Gastronomía Mascotas Moda y Estilo Salud y Bienestar Viajes Gobierno Agricultura Cultura Deportes Educación Fortaleza Justicia Legislatura Municipios Turismo Negocios Categoría para
Peter Lacey Increases His Investment in Hemostemix Inc. Cookie Settings We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use . Necessary Analytics Accept All Accept Selection Reject All × Skip to main content Newsfile Search English Français Deutsch Español Search × Login Username Password Login Newsfile Login Search Français Home About About Company Overview Who We Serve Upcoming Events Careers Services Services Press Release Distribution News Service Overview Global Distribution Additional News Services SEDAR+ Ab … m cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 500 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia
About | Clinical-Stage Regenerative Medicine Company Patient Information Physician Information ACP-01 Show submenu for ACP-01 ACP-01 Clinical Research Conditions Show submenu for Conditions Cardiovascular Ischemia & Angina Chronic Limb Ischemia - CLTI Peripheral Arterial Disease- PAD Vascular Dementia Wound Care Blog Show submenu for Blog Hemostemix Health Hub Hemostemix Video Library About Patient Information Physician Information ACP-01 Show submenu for ACP-01 ACP-01 Clinical Research Conditions Show submenu for Conditions Cardiovascular Ischemia & Angina Chronic Limb Ischemia - CLTI … harlottesville, Virginia. He served in Beirut in 1983, completed a neurosurgery residency at the Medical University of South Carolina, then served as Neurosurgeon for the 4 th Marine Expeditionary Brigade in the Gulf War in 1990-91. He was International Craniospinal Fellow at The National Hospitals for Neurology and Neurosurgery, Queen Square, London. Commander Henderson was then appointed Director of Neurosurgery of the Spine and Craniocervical Junction at Georgetown U … he Principal Investigator, Vancouver site, of the ACP-01 clinical trial for the application of angiogenic cell precursors for no option peripheral arterial disease patients. He has served as the Director of Surgical Research in the UBC Department of Surgery and has written over 120 scientific research articles plus a historical book on the development of vascular surgery at the Vancouver General Hospital, “Audible Bleeding”. He is a Distinguished Fellow of the Society for Vas
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Peter Lacey Increases His Investment in Hemostemix Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Peter Lacey Increases His Investment in Hemostemix Inc. June 22, 2021 | 3 min read Twitter LinkedIn Facebook Email Print Prior to the offering, Mr. Lacey held 4,491,891 Common Shares, or approximately 7.80% of the total issued and outstanding Common Shares. Calgary, Alberta--(Newsfile Corp. - June 21, 2021) - Hemostem … m cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 500 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin